ABITEC Corporation has acquired Larodan AB, a manufacturer and international marketer of high-purity research grade lipids. This strategic acquisition will expand ABITEC’s functional lipid product offerings and scientific capabilities.
Located at the Karolinska Institute in Stockholm, Sweden, Larodan is known for its collaborations with academic and industrial researchers.
“Larodan is a world leader in the field of analytical-grade lipids and their scientific capabilities will not only expand ABITEC’s technical expertise but will also provide us with a strategic R&D location in Europe. The Larodan team has done an exceptional job in the development, manufacturing and global commercialization of their unique and highly specialized lipid reagents and we are thrilled to have them join the ABITEC team. We share a common passion for innovation and lipids, and I look forward to us working together to grow and expand their brand in the US markets and across the globe,” said Jeff Walton, CEO of ABITEC. “The acquisition will undoubtedly bring ABITEC to the forefront of the high-purity lipid market.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
It will also advance ABITEC into the field of Lipidomics which has the potential to offer researchers capabilities to identify the numerous roles of lipids across a vast spectrum of health and disease states at the chemical level. Together, the companies will create a global science-based organization that will use product innovation to propel ABITEC’s scientific and commercial interests.
“We are very happy to find a new home with ABITEC, with whom we share a deep interest in lipids. Together we can immediately offer a more comprehensive service to our American customers including, larger volumes and GMP grades,” said Fredrik Lindgren, selling shareholder and continuing Managing Director of Larodan.